Brief treatment for PTSD: A non-inferiority trial

被引:18
|
作者
Sloan, Denise M. [1 ,2 ]
Marx, Brian P. [1 ,2 ]
Resick, Patricia A. [3 ]
机构
[1] VA Boston Healthcare Syst, VA Natl Ctr PTSD, Boston, MA USA
[2] Boston Univ, Sch Med, Boston, MA 02215 USA
[3] Duke Univ, Sch Med, Durham, NC 27706 USA
关键词
Clinical trial; Posttraumatic stress disorder; Cognitive behavioral therapy; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE PROCESSING THERAPY; IMAGINAL EXPOSURE; WRITTEN EXPOSURE; VETERANS; NONINFERIORITY; HEALTH; VALIDATION; INTERVIEW; MILITARY;
D O I
10.1016/j.cct.2016.04.003
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Prior studies have identified several psychosocial treatment approaches as effective for posttraumatic stress disorder (PTSD). Unfortunately, a substantial minority of individuals who receive these treatments drop out prematurely. Moreover, a considerable number of individuals in need of PTSD treatment do not present for treatment due to time constraints and other barriers to care. Thus, there is a need to develop alternative evidence-based PTSD treatments that have lower treatment dropout rates and address current barriers to receiving care. One recently developed PTSD treatment that has demonstrated efficacy and potentially meets these criteria is Written Exposure Therapy (WET), a 5-session treatment protocol that promotes recovery through writing about the trauma event as well as one's thoughts and feelings about it without any assigned homework. In an ongoing randomized controlled trial (RCT) we are investigating whether WET is equally efficacious as Cognitive Processing Therapy (CPT), a treatment that typically requires more therapist training and more therapy sessions. The study sample consists of 126 adults diagnosed with PTSD who are randomly assigned to either WET (n = 63) or CPT (n = 63). Participants are assessed prior to treatment and 6-, 12-, 24-, 36-, and 60-weeks after the first treatment session. The primary outcome measure is PTSD symptom severity assessed with the Clinician Administered PTSD Scale for DSM-5. Given the prevalence of PTSD and the aforementioned limitations of currently available first-line PTSD treatments, the identification of a brief, efficacious treatment that is associated with reduced patient dropout would represent a significant public health development. Published by Elsevier Inc.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 50 条
  • [31] Assessing non-inferiority of a new treatment in a three-arm trial in the presence of heteroscedasticity
    Hasler, Mario
    Vonk, Richardus
    Hothorn, Ludwig A.
    STATISTICS IN MEDICINE, 2008, 27 (04) : 490 - 503
  • [32] Determining the minimum duration of treatment in tuberculosis: An order restricted non-inferiority trial design
    Serra, Alessandra
    Mozgunov, Pavel
    Davies, Geraint
    Jaki, Thomas
    PHARMACEUTICAL STATISTICS, 2023, 22 (05) : 938 - 962
  • [33] The Non-Inferiority Complex: What Do Non-Inferiority Trials Tell Us?
    Assimon, Magdalene M.
    Cutter, Gary R.
    Bargman, Joanne M.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (04): : 674 - 676
  • [34] Comparing written exposure therapy to Prolonged Exposure for the treatment of PTSD in a veteran sample: A non-inferiority randomized design
    Sloan, Denise M.
    Marx, Brian P.
    Acierno, Ronald
    Messina, Michael
    Cole, Travis A.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2021, 22
  • [35] Confidence interval approach for non-inferiority trial design and analysis
    Luo, XL
    Wei, XY
    Mariam, SF
    CONTROLLED CLINICAL TRIALS, 2003, 24 : 81S - 81S
  • [36] Time to recognize three classes of non-inferiority trial margins
    Saver, Jeffrey L.
    Mistry, Eva
    JOURNAL OF NEUROINTERVENTIONAL SURGERY, 2023, 15 (01) : 2 - 4
  • [37] Rationale for a non-inferiority clinical trial design focused on subpopulations
    Kulkarni, PM
    Meadows, ES
    Ahuja, S
    Muram, D
    Plouffe, L
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (10) : 1641 - 1647
  • [38] Controlled, non-inferiority trial of bupivacaine liposome injectable suspension
    Gordon-Evans, Wanda J.
    Suh, Hanah Y.
    Guedes, Alonso G.
    JOURNAL OF FELINE MEDICINE AND SURGERY, 2020, 22 (10) : 916 - 921
  • [39] Lenvatinib: can a non-inferiority trial change clinical practice?
    Reig, Maria
    Bruix, Jordi
    LANCET, 2018, 391 (10126): : 1123 - 1124
  • [40] Non-inferiority clinical trial. Features and practical considerations
    Serra-Aracil, Xavier
    Fradera, Marc
    CIRUGIA ESPANOLA, 2025, 103 (01): : 49 - 52